Ascentage Pharma Group International income statement AAPG
In fiscal 2024, which ended Dec 31, 2024, Ascentage Pharma Group International reported revenue of $124.4 million. It recorded a net loss of $55.6 million. Diluted earnings per share were -$0.18.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2024
Dec 31, 2024
|
|---|---|
| Revenue |
124
|
| Cost of revenue |
4
|
| Gross profit |
130
|
| Research and development |
130
|
| Selling, general and administrative |
27
|
| Pretax income |
-54
|
| Income tax |
1
|
| Net income |
-56
|
| Basic EPS |
-0.18
|
| Diluted EPS |
-0.18
|
| Weighted average shares, basic |
302
|
| Margins | |
| Gross margin |
104.76%
|
| Pretax margin |
-43.52%
|
| Profit margin |
-44.66%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AAPG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Suzhou , Jiangsu
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2023311
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.